The immunologic and metabolic basis of drug hypersensitivities.
about
Adverse drug reactions.Drug-induced hepatotoxicity: metabolic, genetic and immunological basisSevere Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationMetabolism of hydralazine: relevance to drug-induced lupusHuman anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesteraseRelationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database.Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymusA mouse model of severe halothane hepatitis based on human risk factorsCarbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.Idiosyncratic drug reactions: a mechanistic evaluation of risk factorsNatural killer cells mediate severe liver injury in a murine model of halothane hepatitisN-oxidation of drugs associated with idiosyncratic drug reactions.Metabolism of drugs by leukocytes.Immunohistochemical localization and quantification of the 3-(cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity.The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.Adverse drug reactions with halogenated anesthetics.Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane.Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.Allergic reactions to drugs: current concepts and problems.Drug allergy. Best diagnostic and treatment approaches.Drug-protein conjugation and its immunological consequences.Neoantigens associated with halothane hepatitis.Human biology-based drug safety evaluation: scientific rationale, current status and future challenges.The role of metabolic activation in drug toxicity.Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology.In vitro analysis of metabolic predisposition to drug hypersensitivity reactions.Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury.The role of reactive drug metabolites in immune-mediated adverse drug reactions.Digging up the human genome: current progress in deciphering adverse drug reactions.Drug-induced allergic hepatitis: does isaxonine fall into this category?Immunochemical methods of studying the mechanism of diclofenac-induced hepatitis [corrected].Immunogenicity studies of a synthetic antigen of alpha methyl dopa.Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase.Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites.Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism.Stereoselective metabolism of halothane enantiomers to trifluoroacetylated liver proteins.
P2860
Q24524192-ABB5DDAA-5D4B-4FC9-99AF-A2293F810643Q26991809-43C80DD8-78A8-4C1A-A93E-245C4E6BB118Q28076600-11329F29-EF3C-455E-9C51-063177861E45Q28238389-D47BABCA-19C5-4A9D-A765-2DA38B2D9CC9Q28360104-E5FF6939-00E2-4E88-BFDF-9200FF7053C4Q30912283-AD0BA0B8-2C8D-49C0-867D-BB195079A4E1Q33396340-105B2275-601C-44FC-A779-F234479E76EDQ33741226-A80653BF-99AE-4A0E-9D2C-0A8779CA9B9DQ33861938-A898AD5F-8455-4F0F-95E2-22EC8BDBF1D1Q34358782-B324F992-1FC8-4438-9741-8AA3E43BFD1AQ34403403-91D6233B-EF14-497A-834A-5DBA68EA60ACQ34701790-A41082F3-10A5-4E71-9FF3-C59D4E918230Q34819168-C799AE4E-7EF8-4667-88A9-E95C9EECF35FQ34945908-F54FD210-5759-4511-8700-2D815FD1F9DAQ35830716-82E43EFA-56BC-4F9B-98F5-08FB48FB923CQ36312078-3E74B85F-CB16-4071-87C8-911BF75519AFQ36871056-948AFFE3-083D-4F66-BAE9-2E04256BAB3AQ37176028-BC33F70B-87DD-462D-A9C8-3D10DBAA72ACQ37404717-C2719F01-5F80-42A4-AC09-8F156B8D87CEQ37472027-AEE094EF-903C-4EF1-9B73-490D31480906Q37724173-022B1EE9-3EB9-4E7D-89F8-96B464D7A1B8Q37850334-306960E2-0680-492A-9656-DE1EC844A96BQ37911262-88945001-6010-47FE-9CBA-F0C8D6930544Q37944829-B2210BDB-1D90-453A-914A-FD1D3B137702Q38709418-EA294709-DE3A-4482-9F3A-F630C0D2515EQ38763000-77D28F3A-0E9C-4B0C-A127-732E735616DCQ40392352-1252A9EA-73CA-445C-BB57-453F0D1C14BAQ40422942-AAEA0D26-A38F-4A69-A2CE-2D395BEC4E1DQ40564205-89D8AB57-087B-4F83-90BB-1FABD3B92204Q40817414-96A31FAD-272B-4AE3-8689-69B55395B7FBQ41656963-839AF7A5-802E-42F1-AF4B-DB7A1949616EQ41889353-F14EBE5F-FF93-48D2-992B-F0CF855C02FBQ41967726-621039CC-5C63-4925-A897-F0A38A28C989Q42283436-96C5341F-B191-4D2A-8D2E-02A8B06CF599Q42287517-A3A38299-E18D-412B-8461-B4B7D45B0748Q42289152-DA692677-CD7F-4E15-B966-7D4803B591C5Q43222882-18EDBA6D-2FDC-4919-AA0A-A864AAABA5A8Q43699660-F077A7DD-31F9-47CA-A26C-E71E0DDA4F79Q50343146-7E4B69CF-0ADE-4D08-BD55-F41FC107ACEAQ51616395-69B3AF62-B9A7-49EA-93FE-83EB199934DF
P2860
The immunologic and metabolic basis of drug hypersensitivities.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
The immunologic and metabolic basis of drug hypersensitivities.
@en
The immunologic and metabolic basis of drug hypersensitivities.
@nl
type
label
The immunologic and metabolic basis of drug hypersensitivities.
@en
The immunologic and metabolic basis of drug hypersensitivities.
@nl
prefLabel
The immunologic and metabolic basis of drug hypersensitivities.
@en
The immunologic and metabolic basis of drug hypersensitivities.
@nl
P2093
P1476
The immunologic and metabolic basis of drug hypersensitivities.
@en
P2093
P304
P356
10.1146/ANNUREV.PA.28.040188.002055
P577
1988-01-01T00:00:00Z